Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 470-472 , March 2008

Dissecting the NPY signaling cascade between cardiac sympathetic and parasympathetic nerves

  • Lev Protas
    • ,
  • Richard B. Robinson

      Affiliations

    • Corresponding Author InformationCorresponding author. Columbia University, Department of Pharmacology, 630 West 168th Street, Room PH7W-318, New York, NY 10032, USA. Tel.: +1 212 305 8371; fax: +1 212 305 8780.

Received 26 December 2007 ,Accepted 2 January 2008.

References 

  1. Vanhoutte P, Levy M. Prejunctional cholinergic modulation of adrenergic neurotransmission in the cardiovascular system. Am J Physiol. 1980;238(3):H275–H281
  2. Potter E. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?. Neurosci Lett. 1985;54(2–3):117–121
  3. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. Mar 1 1998;50(1):143–150
  4. Weinberg DH, Sirinathsinghji DJS, Tan CP, Shiao LL, Morin N, Rigby MR, et al. Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem. Jul 12 1996;271(28):16435–16438
  5. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci. 2003;60(2):350–377
  6. Balasubramaniam A, Grupp I, Matlib M, Benza R, Jackson R, Fischer J, et al. Comparison of the effects of neuropeptide Y (NPY) and 4-norleucine-NPY on isolated perfused rat hearts; effects of NPY on atrial and ventricular strips of rat heart and on rabbit heart mitochondria. Regul Pept. 1988;21(3–4):289–299
  7. Bryant SM, Ryder KO, Hart G. Effects of neuropeptide Y on cell length and membrane currents in isolated guinea pig ventricular myocytes. Circ Res. Oct 1991;69(4):1106–1113
  8. Piper HM, Millar BC, McDermott BJ. The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn Schmiedebergs Arch Pharmacol. Sep 1989;340(3):333–337
  9. Franco C, Lundberg JM, Dahlof C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand. Jul 1985;124(3):361–369
  10. Heredia MdP, Delgado C, Pereira L, Perrier R, Richard S, Vassort G, et al. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol. Jan 2005;38(1):205–212
  11. Scott NA, Michel MC, Boublik JH, Rivier JE, Motomura S, Crum RL, et al. Distinction of NPY receptors in vitro and in vivo. II. Differential effects of NPY and NPY-(18-36). Am J Physiol Heart Circ Physiol. Jul 1 1990;259(1):H174–H180
  12. Allen J, Gjorstrup P, Bjorkman J, Ek L, Abrahamsson T, Bloom S. Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand. 1986;126(3):405–411
  13. Serone AP, Angus JA. Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria. Br J Pharmacol. May 1999;127(2):383–390
  14. Wahlestedt C, Wohlfart B, Hakanson R. Effects of neuropeptide Y (NPY) on isolated guinea-pig heart. Acta Physiol Scand. 1987;129(4):459–463
  15. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature. Apr 19 2001;410(6831):940–944
  16. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. Jul 27 1998;83(2):187–195
  17. Goldberg Y, Taimor G, Piper HM, Schluter KD. Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am J Physiol. Nov 1998;275(5 Pt 1):C1207–C1215
  18. Millar BC, Schluter KD, Zhou XJ, McDermott BJ, Piper HM. Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am J Physiol. May 1994;266(5 Pt 1):C1271–C1277
  19. Pellieux C, Sauthier T, Domenighetti A, Marsh DJ, Palmiter RD, Brunner HR, et al. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A. Feb 15 2000;97(4):1595–1600
  20. Protas L, Qu J, Robinson RB. Neuropeptide Y: neurotransmitter or trophic factor in the heart?. News Physiol Sci. Oct 1 2003;18(5):181–185
  21. Lundberg J, Hua X, Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand. 1984;121(4):325–332
  22. Rump LC, Riess M, Schwertfeger E, Michel MC, Bohmann C, Schollmeyer P. Prejunctional neuropeptide Y receptors in human kidney and atrium. J Cardiovasc Pharmacol. May 1997;29(5):656–661
  23. Ilebekk A, Björkman J, Nordlander M. Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart. J Cardiovasc Pharmacol. Oct 2005;46(4):474–480
  24. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of exogenous neuropeptide Y on automaticity of isolated Purkinje fibers and atrium. J Mol Cell Cardiol. May 1996;28(5):967–975
  25. Burger AJ, Aronson D. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. J Card Fail. Jun 2001;7(2):122–128
  26. Cohn J, Levine T, Olivari M, Garberg V, Lura D, Francis G, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823
  27. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation. Oct 13 1998;98(15):1510–1516
  28. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol. Feb 2001;132(4):861–868
  29. Smith-White MA, Wallace D, Potter EK. Sympathetic–parasympathetic interactions at the heart in the anaesthetised rat. J Auton Nerv Syst. Feb 1999;75(2–3):171–175
  30. Moriarty M, Gibbins I, Potter E, McCloskey D. Comparison of the inhibitory roles of neuropeptide Y and galanin on cardiac vagal action in the dog. Neurosci Lett. 1992;139(2):275–279
  31. Potter E. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett. 1987;83(1–2):101–106
  32. Smith-White MA, Herzog H, Potter EK. Role of neuropeptide Y Y2 receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept. Feb 15 2002;103(2–3):105–111
  33. Smith-White MA, Iismaa TP, Potter EK. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse.. Br J Pharmacol. Jul 29 2003;140(1):170–178
  34. Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump L. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y 2-receptors. Naunyn Schmiedebergs Arch Pharmacol. May 1 2004;369(5):455–461
  35. Smith-White MA, Herzog H, Potter EK. Cardiac function in neuropeptide Y Y4 receptor-knockout mice. Regul Pept. Dec 31 2002;110(1):47–54
  36. Herring N, Lokale NN, Danson EJ, Heaton DA, Paterson DJ. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol. 2008;44:477–485
  37. Jonsson-Rylander AC, Nordlander M, Svindland A, Ilebekk A. Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides. Feb 2003;24(2):255–262
  38. Nicholl SM, Bell D, Paul Spiers J, McDermott BJ. Neuropeptide Y Y1 receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. Eur J Pharmacol. Apr 19 2002;441(1–2):23–34
  39. McDermott BJ, Millar BC, Dolan FM, Bell D, Balasubramaniam A. Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol. 1997;336(2–3):257–265
  40. Courtice GP, Potter EK, McCloskey DI. Inhibition of cardiac vagal action by galanin but not neuropeptide Y in the brush-tailed possum Trichosurus vulpecula. J Physiol. Feb 1 1993;461(1):379–386
  41. Potter EK, Smith-White MA. Galanin modulates cholinergic neurotransmission in the heart. Neuropeptides. Jun 2005;39(3):345–348

PII: S0022-2828(08)00004-7

doi: 10.1016/j.yjmcc.2008.01.001

Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 470-472 , March 2008

Article Tools